Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01903148
NCT01903148CompletedNot Applicable

ANEMIA MANAGEMENT IN CHRONIC KIDNEY DISEASE NOT ON DIALYSIS PATIENTS AFTER THE ERBP WORKING GROUP RECOMMENDATIONS

Fundación Senefro29 sites in 1 country455 target enrollmentStarted: October 2011Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
455
Locations
29
Primary Endpoint
% Patients Achieving Target Hemoglobin Levels
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to evaluate the impact of the last recommendations of the European Anemia Working Group ERBP in the anemia management in the achievement of the therapeutic goal of Hb 11-12 g/dL.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Adults patients with anemia secondary to chronic kidney disease (CKD) not on dialysis.
  • •Patients starting anemia treatment (naïve) after six months of the last recommendations of the European Anemia Working Group ERBP (January 2011).
  • •Patients in treatment who changed from previous ESA treatment since January 2011 (converted patients

Exclusion Criteria

  • •Patients in Erythropoiesis Stimulating Agents (ESA) dose adjustment period.
  • •Kidney transplant patients.

Outcomes

Primary Outcomes

% Patients Achieving Target Hemoglobin Levels

Time Frame: 1 day because is a crosssectional study with only a visit

% patients with Hb levels between 11-12 mg/dl

Secondary Outcomes

  • Iron Treatment(1 day)
  • Patients With Hb<11(1 day)
  • Patients With Hb>12(1 day)
  • % Patients With Erythropoiesis Stimulating Agents (ESA) Therapy(1 day)
  • Hemoglobin Levels Per Type of Patients(1 day)

Investigators

Sponsor
Fundación Senefro
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (29)

Loading locations...

Similar Trials

Not yet recruiting
Unknown
This study aims to understand better approaches for treating anemia in patients with CKD. By doing so, it aspires to make a significant contribution to the enhancement of patient care and overall outcomes.
CTRI/2024/01/061359ational Institute of Pharmaceutical Education and Research, Mohali
Completed
Not Applicable
Mean Reticulated Haemoglobin (Hb) Content (RetHe) Analysis of Renal PatientsFunctional Iron DeficiencyEnd-Stage Renal Failure
NCT01126905University of Ulster250
Recruiting
Phase 4
This research aims to understand better treatment approaches for managing anemia in patients with CKD, with the ultimate goal of significantly enhancing patient care and overall treatment outcomes.
CTRI/2024/05/066877ational Institute of Pharmaceutical Education and Research, Mohali
Completed
Not Applicable
Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney DiseaseChronic Kidney DiseaseAnemiaCardiomyopathy
NCT00883415University of Maryland, Baltimore20
Recruiting
Unknown
Elucidation of clinical implication of cardiorenal anemia syndromeheart failure, chronic renal disease, anemia
JPRN-jRCT1070230109Matsushima Shouji16,238